Antibiotic-resistant infections are on the rise in Europe, with a significant 72% increase in bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae since 2019, according to a new report from the European Centre for Disease Prevention and Control (ECDC) released on European Antibiotic Awareness Day. The data raises serious concerns about the efficacy of treatment options available for this type of hospital-acquired pathogen, which is resistant to many current antibiotics.
This report highlights the European Union’s struggle to meet several targets aimed at combatting antimicrobial resistance (AMR) by 2030. The EU Council adopted a recommendation in June 2023 that established 2019 as the baseline year for evaluating progress, but recent findings show mixed results across multiple regions in the EU. Of particular concern is the increase in bloodstream infections, with K. pneumoniae exhibiting resistance patterns that are expected to hamper clinical outcomes.
While overall human antibiotic consumption decreased by 5% compared to 2019, this remains significantly short of the 20% reduction goal set for 2030. However, there has been some improvement in the quality of antibiotic prescribing, as the share of first-line antibiotics under the World Health Organization’s Access classification rose from 61.1% to 62.5%, nearing the target of 65%.
Other trends regarding resistant infections show a mixed picture. In contrast to the rise in K. pneumoniae infections, meticillin-resistant Staphylococcus aureus infections fell by 19%, surpassing the goal of a 15% reduction. However, bloodstream infections caused by another resistant bacterium, E. coli, rose by 16.4%, exceeding the targeted 10% decline.
The report also indicates that most antibiotic exposure occurs in community settings, with outpatient care accounting for 90% of total human consumption. The ECDC is addressing this through a 2026 public health initiative targeting pediatric antibiotic use. The campaign emphasizes to caregivers that many common childhood illnesses, such as colds and sore throats, are viral and do not require antibiotics.
ECDC Director Pamela Rendi-Wagner noted that advancements in genomic surveillance are crucial for understanding the spread of resistant strains. The ECDC operates three transnational monitoring networks: EARS-Net for tracking resistance, ESAC-Net for monitoring consumption, and EURGen-Net for genomic surveillance of resistant bacteria. These networks help identify the geographic spread and resistance mechanisms of multidrug-resistant clones.
Efforts to manage AMR will require ongoing intervention from health authorities, including a combined approach of infection control, stewardship programs, enhanced diagnostics, and integrated surveillance. The ECDC has proposed guidelines for infection prevention and control within healthcare facilities and is emphasizing data-driven monitoring through tools like the hyFive digital application.
As Europe grapples with rising AMR challenges, specialized surveillance networks provide vital operational intelligence that informs public health strategies. By analyzing the genetic traits and spread of resistant pathogens, authorities can coordinate effective treatments and identify urgent areas needing new antimicrobial development.


